A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 680 participants.

Also called NCT05953480

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 680 participants (enrolled count) (from the registry)
Sponsor
  • Shionogi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05953480
  • EU CT 2022-501890-38-00
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Belgium, China, Czechia, Finland, Germany, Greece, Hong Kong SAR China, Hungary, Israel, Japan, Serbia, Singapore, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05953480. Randomized; double masking; primary purpose treatment. Start 2023-07-14 (actual); primary completion 2026-06-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
Acronym
Revive
Condition
Acute Ischemic Stroke
Intervention (Biological)
Redasemtide
Intervention (Drug)
Placebo
Lead sponsor
Shionogi (class: industry)

Record details

Record id
cardio:ct-nct05953480
Content hash
1c7be906d778b60cecd4d2224da0bc05b4f9b00911ab174a78f67594d9a21b80